We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Thermo Fisher Scientific (TMO - Free Report) closed at $572.25, marking a +1.72% move from the previous day. The stock outpaced the S&P 500's daily gain of 1.24%. At the same time, the Dow added 1.23%, and the tech-heavy Nasdaq gained 0.15%.
Coming into today, shares of the maker of scientific instrument and laboratory supplies had gained 2.22% in the past month. In that same time, the Medical sector gained 0.3%, while the S&P 500 lost 2.45%.
Wall Street will be looking for positivity from Thermo Fisher Scientific as it approaches its next earnings report date. In that report, analysts expect Thermo Fisher Scientific to post earnings of $6.20 per share. This would mark a year-over-year decline of 14.01%. Meanwhile, our latest consensus estimate is calling for revenue of $10.63 billion, up 7.32% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $22.52 per share and revenue of $42.15 billion. These totals would mark changes of -10.39% and +7.48%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Thermo Fisher Scientific. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Thermo Fisher Scientific is currently a Zacks Rank #3 (Hold).
Investors should also note Thermo Fisher Scientific's current valuation metrics, including its Forward P/E ratio of 24.98. This valuation marks a discount compared to its industry's average Forward P/E of 32.97.
We can also see that TMO currently has a PEG ratio of 1.78. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.1 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 182, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Thermo Fisher Scientific (TMO - Free Report) closed at $572.25, marking a +1.72% move from the previous day. The stock outpaced the S&P 500's daily gain of 1.24%. At the same time, the Dow added 1.23%, and the tech-heavy Nasdaq gained 0.15%.
Coming into today, shares of the maker of scientific instrument and laboratory supplies had gained 2.22% in the past month. In that same time, the Medical sector gained 0.3%, while the S&P 500 lost 2.45%.
Wall Street will be looking for positivity from Thermo Fisher Scientific as it approaches its next earnings report date. In that report, analysts expect Thermo Fisher Scientific to post earnings of $6.20 per share. This would mark a year-over-year decline of 14.01%. Meanwhile, our latest consensus estimate is calling for revenue of $10.63 billion, up 7.32% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $22.52 per share and revenue of $42.15 billion. These totals would mark changes of -10.39% and +7.48%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Thermo Fisher Scientific. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Thermo Fisher Scientific is currently a Zacks Rank #3 (Hold).
Investors should also note Thermo Fisher Scientific's current valuation metrics, including its Forward P/E ratio of 24.98. This valuation marks a discount compared to its industry's average Forward P/E of 32.97.
We can also see that TMO currently has a PEG ratio of 1.78. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.1 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 182, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.